Cerebrolysin vs Davunetide

Standardized mixture of neuropeptides derived from porcine brain proteins; mimics endogenous neurotrophic factors (BDNF, NGF, CNTF); promotes neurogenesis and synaptic plasticity

Cerebrolysin is a brain-derived polypeptide preparation derived from porcine cortical tissue, composed of low-molecular-weight neuropeptides and free amino acids that cross the blood-brain barrier and exert neurotrophic and neuroprotective effects. It is proposed to mimic endogenous neurotrophic factors, supporting neuronal survival, synaptic plasticity, and metabolic activity in damaged or degenerating brain tissue through multiple growth factor-like pathways. A Cochrane systematic review and multiple controlled clinical trials from Eastern European research groups have evaluated cerebrolysin for vascular dementia and stroke-related cognitive impairment, with mixed results that suggest potential benefit in specific post-stroke populations. Cerebrolysin is not FDA-approved; it is approved and widely used in Russia, Eastern Europe, and some Asian countries as a prescription neuroprotective treatment, and its evidence base reflects predominantly Eastern European clinical methodology with variable trial quality. Cerebrolysin price and access: Cerebrolysin is not available through standard US pharmacy channels; it is a prescription medication in the countries where it is approved (Russia, Eastern Europe, China, South Korea, and others) and is not FDA-approved. In markets where it is approved, cerebrolysin is administered intravenously in clinical settings — IV infusion courses of 10–20 sessions are the standard research and clinical protocol, with treatment costs varying significantly by country and clinic. Importation for personal use exists in a legal grey area in the United States; some wellness and peptide clinics may offer cerebrolysin as part of supervised protocols. Cancer-adjacent research: cerebrolysin's neurotrophic properties have drawn preclinical research interest in the context of chemotherapy-induced cognitive impairment (chemobrain), where neuroprotection during and after oncology treatment is a research priority. Autism spectrum disorder research: small controlled trials from Eastern European groups have evaluated cerebrolysin for speech and behavioral development in children with ASD, with mixed results; this remains an exploratory research area with no established clinical consensus. Stroke rehabilitation remains cerebrolysin's strongest evidence base, with multiple controlled trials evaluating cognitive and functional recovery in post-stroke patients.

Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation.

Davunetide (AL-108; NAP; NAPVSIPQ) is a synthetic octapeptide derived from activity-dependent neuroprotective protein (ADNP), initially identified as a neuroprotective sequence from ADNP and investigated in clinical trials as a candidate treatment for cognitive impairment associated with schizophrenia and tauopathies including progressive supranuclear palsy. Davunetide is proposed to stabilize microtubule dynamics by interacting with tubulin and preventing tau hyperphosphorylation-related cytoskeletal disruption, and preclinical models demonstrated neuroprotective and procognitive effects at nanomolar concentrations. Clinical investigation included Phase 2 trials examining cognitive outcomes and MRS neuroimaging biomarkers in schizophrenia patients, and a Phase 2/3 trial in progressive supranuclear palsy; results showed some neurochemical effects but no consistent meaningful cognitive improvement across clinical endpoints, and the PSP program did not meet its primary outcomes. Davunetide has no FDA approval and no approved indication in any jurisdiction; clinical development has been discontinued following negative trial outcomes, and while its preclinical neuroprotective profile remains scientifically interesting, the clinical evidence does not establish efficacy for cognitive enhancement or neuroprotection in any condition.